These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 26865419)

  • 1. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
    Takigawa H; Kitadai Y; Shinagawa K; Yuge R; Higashi Y; Tanaka S; Yasui W; Chayama K
    Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer.
    Shinagawa K; Kitadai Y; Tanaka M; Sumida T; Onoyama M; Ohnishi M; Ohara E; Higashi Y; Tanaka S; Yasui W; Chayama K
    Int J Cancer; 2013 Feb; 132(4):813-23. PubMed ID: 22821812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib mesylate inhibits proliferation of human colonic stromal fibroblasts in vitro and in vivo.
    Wang ZH; Li Q; Ruan SQ; Xiao Q; Liu Y; Hu YT; Hu LF; Chen HY; Zheng S; Zhang SZ; Ding KF
    J Zhejiang Univ Sci B; 2014 Aug; 15(8):701-12. PubMed ID: 25091988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
    Wilhelm SM; Dumas J; Adnane L; Lynch M; Carter CA; Schütz G; Thierauch KH; Zopf D
    Int J Cancer; 2011 Jul; 129(1):245-55. PubMed ID: 21170960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.
    Kitadai Y; Sasaki T; Kuwai T; Nakamura T; Bucana CD; Fidler IJ
    Am J Pathol; 2006 Dec; 169(6):2054-65. PubMed ID: 17148668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib in metastatic colorectal cancer.
    Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stem cells enhance growth and metastasis of colon cancer.
    Shinagawa K; Kitadai Y; Tanaka M; Sumida T; Kodama M; Higashi Y; Tanaka S; Yasui W; Chayama K
    Int J Cancer; 2010 Nov; 127(10):2323-33. PubMed ID: 20473928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model.
    Abou-Elkacem L; Arns S; Brix G; Gremse F; Zopf D; Kiessling F; Lederle W
    Mol Cancer Ther; 2013 Jul; 12(7):1322-31. PubMed ID: 23619301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
    Mehta M; Griffith J; Panneerselvam J; Babu A; Mani J; Herman T; Ramesh R; Munshi A
    Int J Radiat Biol; 2021; 97(8):1109-1120. PubMed ID: 32052681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy.
    Kuwai T; Nakamura T; Sasaki T; Kitadai Y; Kim JS; Langley RR; Fan D; Wang X; Do KA; Kim SJ; Fidler IJ
    Clin Exp Metastasis; 2008; 25(4):477-89. PubMed ID: 18324358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
    Liu YC; Tsai JJ; Weng YS; Hsu FT
    Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
    Pietras K; Pahler J; Bergers G; Hanahan D
    PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
    Ou DL; Chen CW; Hsu CL; Chung CH; Feng ZR; Lee BS; Cheng AL; Yang MH; Hsu C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.
    Breitkreutz I; Podar K; Figueroa-Vazquez V; Wilhelm S; Hayden PJ; Anderson KC; Raab MS
    Ann Hematol; 2018 May; 97(5):839-849. PubMed ID: 29359239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib for cancer.
    Strumberg D; Schultheis B
    Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
    Huynh H; Ong R; Zopf D
    J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of regorafenib and its current and potential future role in cancer therapy.
    Davis SL; Eckhardt SG; Messersmith WA; Jimeno A
    Drugs Today (Barc); 2013 Feb; 49(2):105-15. PubMed ID: 23462625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
    Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
    Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.